CI enters its July 30 earnings release with bearish conviction at its lowest ebb in months — shorts are covering, borrow is cheap, and options traders are not reaching for protection.
The short retreat has continued since the last published note. Short interest has edged down a further 8% over the past week to 2.09% of free float, extending a drawdown that has now erased more than 21% of the short book over the past month. The position has shrunk from roughly 7.6 million shares at the start of July to below 5.6 million. Borrow conditions offer no friction to further covering: availability has actually loosened further to an extraordinary 8,326% — nearly 198 million shares sit available to lend against just 5.6 million borrowed — and the cost to borrow has fallen 21% on the week to 0.25%. The ORTEX short score has drifted to 33.3, its lowest point in the recent window and down from 36.5 two weeks ago. Nothing in the lending market is keeping shorts in the trade. The stock itself has recovered slightly, up 2.9% on the week to $289.57, recouping part of the ground lost in the prior note's reported 4.2% pullback.
Options traders are equally unmoved by the proximity of the print. The put/call ratio is running at 0.43, essentially in line with its 20-day average of 0.44 and well away from any defensive extreme. The 52-week range on the PCR runs from 0.35 to 0.64, placing current positioning near the middle of the band — neither complacent nor hedged. There is no signal here of elevated pre-earnings anxiety.
The analyst debate is less settled. Bernstein lifted its target to $381 earlier this month, maintaining an Outperform. The broader consensus mean sits near $341, implying roughly 18% upside from current levels. But the bullish camp faces a credible challenge: Barclays downgraded to Equal-Weight in late May and Deutsche Bank moved to Hold around the same time, both flagging the risk that Evernorth's transition to a rebate-free model compresses near-term margins more than the market is pricing. Bulls counter that the exit from the individual Exchange business removes a persistent drag and that Evernorth's pharmacy benefit management scale is a structural advantage. The EV/EBITDA multiple of 7.1x and a trailing P/E of 9.0x suggest the stock is not priced for perfection — bears need an actual earnings miss to make their case stick.
The historical pattern is worth noting. The two most recent quarterly prints both produced day-one losses of roughly 3–4%, with the five-day return remaining negative each time. The earnings report on July 30 will therefore test whether Cigna's margin trajectory in the Evernorth segment has turned a corner, or whether the cost headwinds that have weighed on the past two prints are still working through the numbers.
See the live data behind this article on ORTEX.
Open CI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
